Rev of $536K over 2 months...look at what others in similar...

First 8 Last

Share
Profile

Follow
Mayney

661 Posts.

2

29/02/16

17:14

Post #: 17146071
Share

Originally posted by jordantravispyne ↑

Excellent result - My own key breakdown

Revenue
- Revenue from continuing operations as $536k after two months since acquisition (straight line annualisation would have the full year result at $3.216M matching Baillieu Holst's report estimate of $3.2M [Note: Baillieu would have not included the months before the acquisition in this estimate though as I did. However, it appears revenue is on track with current growth profile])

View attachment 149632
- Revenue primarily derived from Dash Digital as expected. Velpic growing strong with revenue $72,650 from two months.

Expenses
- Net loss after accounting for non-reccuring items was $642k (all related to RTO)

Cash Flow
- Cash burn was high but should exclude non-reccuring items (all related to RTO)
- Adjusted cash burn from operating activities was $849k (on target with Baillieu Holst's research report cash burn target of $0.3-$0.4M per month [Note: first months were always going to be highest cash burn as figures will decline as revenues grow).

- Cash received from operations was 71% of revenues.

Summary

Everything is on track which is the absolute most important thing. In my opinion the real risk of this company is the cash burn (I really do not want a second raising) but I am very satisfied with the way things are tracking!

Excellent work to the team!

Excited to quietly read all your own opinions on the result for the rest of the day. As expected nothing new necessarily from the quarterly but good to see the Directors have a tight grasp on managing a business.

Here is to a fantastic SME launch and continued prosperity for all!

View attachment 149635

Expand

Rev of $536K over 2 months...look at what others in similar sector MC and SP are at compared to this with less revenue!
This is a no brainer but just ain't getn the love ATM.
Let's go team, fire her up!
GL holders

VPC Price at posting: 5.9¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Bitcoin investors need to know the risks

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

ASX hits all time high out the gate on Friday trades following bullish US inflation data

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

There are more pages in this discussion • 1 more message in this thread...

First 8 Last

Add HHI (ASX) to my watchlist

Rev of $536K over 2 months...look at what others in similar...

Top Stories

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Bitcoin investors need to know the risks

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Nimy to raise $1.21M to explore 'newsy' WA targets

ASX hits all time high out the gate on Friday trades following bullish US inflation data

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Immutep reports strong response rate from immunotherapies treating carcinomas

Featured News